FDAnews
www.fdanews.com/articles/198919-verona-pharma-launches-covid-19-pilot-study-for-inhaler-delivered-ensifentrine
Verona Pharma logo

Verona Pharma Launches COVID-19 Pilot Study for Inhaler-Delivered Ensifentrine

September 9, 2020

UK-based Verona Pharma has begun a pilot study to assess the efficacy and safety of ensifentrine, a bronchodilator delivered by metered-dose inhaler, in hospitalized COVID-19 patients.

Clinical data from trials involving more than 1,300 participants have shown that the drug provides improved oxygenation, reduces lung inflammation and improves mucus clearance, and is well-tolerated.

The new pilot study will evaluate the drug’s effect on outcomes including infection recovery and the reduction in supplemental oxygen use. If the pilot proves successful, Verona will continue researching the metered-dose inhaler product as a COVID-19 treatment.

View today's stories